Otsuka Holdings Co., Ltd., announced that the changes of directors detailed below were determined today at a meeting of its Board of Directors.
The resolution is subject to approval at the annual general shareholders' meeting and a meeting of its Board of Directors scheduled for March 27, 2020.
Changes of Directors
Name
New Position (as of March 27, 2020)
Makoto Inoue
Executive Director
Name
New Position (as of March 27, 2020)
Mayo Mita
Outside Director
Resignation of Director
Name
Current Position
Atsumasa Makise
Executive Director
Otsuka Foods Co., Ltd. determined the changes of directors detailed below at a meeting of its Board of Directors on February 12, 2020. The resolution is subject to approval at the annual general shareholders' meeting scheduled for March 12, 2020.
Name
Atsumasa Makise
New Position
Chairman (Board Member)
Otsuka Foods Co., Ltd.
Previous Position
President and Representative Director
Otsuka Foods Co., Ltd.
Effective Date
March 12, 2020
-1-
Attachments
Original document
Permalink
Disclaimer
Otsuka Holdings Co. Ltd. published this content on 14 February 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 February 2020 05:13:06 UTC
Otsuka Holdings Co, Ltd. is a holding company organised around 4 areas of activity:
- manufacture and sale of pharmaceutical products (65.2% of sales): prescription drugs and intravenous solutions mainly for the treatment of central nervous system disorders, cancer, cardiovascular, gastrointestinal and ophthalmic diseases. In addition, the group sells diagnostic products and medical devices;
- manufacture and sale of nutraceutical products (25.1%): functional foods and beverages, OTC products, nutritional supplements;
- production of mineral waters, beverages and foods (2.1%);
- other (7.5%): manufacture of functional chemicals and fine chemicals, provision of logistics services, manufacture of electronic products, etc.
Net sales by source of income are divided between sales of products (93.8%), sales of licences and royalties (1.8%) and other (4.4%).
Net sales are distributed geographically as follows: Japan (43.2%), North America (34%),